• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.3880 +0.0529 (+15.79%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 416,038
    Open 0.3700
    Bid (Size) 0.3624 (60)
    Ask (Size) 0.3965 (65)
    Prev. Close 0.3351
    Today's Range 0.3520 - 0.3900
    52wk Range 0.3150 - 5.010
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
    The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Provides Half Year 2024 Corporate Update
    Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
    From Mainz BioMed NV
    Via GlobeNewswire

    Performance

    YTD
    -66.84%
    -66.84%
    1 Month
    -42.94%
    -42.94%
    3 Month
    -64.40%
    -64.40%
    6 Month
    -65.36%
    -65.36%
    1 Year
    -91.57%
    -91.57%

    More News

    Read More
    Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
    Via Benzinga
    Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
    Via News Direct
    Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
    Via News Direct
    Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Results of 2024 Annual General Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
    From Mainz BioMed NV
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
    Via Benzinga
    Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
    From Mainz BioMed NV
    Via GlobeNewswire
    mRNA Is Promising A Breakthrough In Fighting Cancer
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
    From Mainz BioMed NV
    Via GlobeNewswire
    The Pharmaceutical Industry Finds Itself At A Historical Crossroads
    Via Benzinga
    MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Mainz Biomed Reports Full Year 2023 Financial Results
    From Mainz BioMed NV
    Via GlobeNewswire
    Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    From Mainz BioMed NV
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.